Correction to New pharmacological strategies for protecting kidney function in type 2 diabetes(The Lancet Diabetes & Endocrinology (2019) 7(5) (397–412), (S2213858718302638), (10.1016/S2213-8587(18)30263-8));New pharmacological strategies for protecting kidney function in type 2 diabetes

The Lancet Diabetes and Endocrinology

Volumn 7, Issue 5, 2019, Pages 397-412

  Muskiet, Marcel H A ^a   Wheeler, David C ^b   Heerspink, Hiddo J L ^c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN RECEPTOR ANTAGONIST; INCRETIN; MINERALOCORTICOID ANTAGONIST; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ATRASENTAN; FINERENONE; NAPHTHYRIDINE DERIVATIVE;

BLOOD PRESSURE REGULATION; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; EVIDENCE BASED PRACTICE; GLYCEMIC CONTROL; HUMAN; KIDNEY FUNCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; POPULATION RISK; PRIORITY JOURNAL; RENAL PROTECTION; REVIEW; RISK FACTOR; TREATMENT OUTCOME; CHRONIC KIDNEY FAILURE; COMPLICATION;

ANTIHYPERTENSIVE AGENTS; ATRASENTAN; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; ENDOTHELIN RECEPTOR ANTAGONISTS; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; MINERALOCORTICOID RECEPTOR ANTAGONISTS; NAPHTHYRIDINES; RENAL INSUFFICIENCY, CHRONIC; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS;

EID: 85062226175     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(19)30035-X     Document Type: Erratum

References (125)

1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3 (2013), 1–150.
2. Fox, CS, Matsushita, K, Woodward, M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet 380 (2012), 1662–1673.
3. de Zeeuw, D, Heerspink, HJ, Unmet need in diabetic nephropathy: failed drugs or trials?. Lancet Diabetes Endocrinol 4 (2016), 638–640.
4. Muskiet, MHA, Heerspink, HJL, van Raalte, DH, SGLT2 inhibition: a new era in renoprotective medicine?. Lancet Diabetes Endocrinol 5 (2017), 569–571.
5. Muskiet, MH, Tonneijck, L, Smits, MM, Kramer, MH, Heerspink, HJ, van Raalte, DH, Pleiotropic effects of type 2 diabetes management strategies on renal risk factors. Lancet Diabetes Endocrinol 3 (2015), 367–381.
6. Wong, MG, Perkovic, V, Chalmers, J, et al. Long-term benefits of intensive glucose control for preventing end-stage kidney disease: ADVANCE-ON. Diabetes Care 39 (2016), 694–700.
7. Roussel, R, Lorraine, J, Rodriguez, A, Salaun-Martin, C, Overview of data concerning the safe use of antihyperglycemic medications in type 2 diabetes mellitus and chronic kidney disease. Adv Ther 32 (2015), 1029–1064.
8. Hung, SC, Chang, YK, Liu, JS, et al. Metformin use and mortality in patients with advanced chronic kidney disease: national, retrospective, observational, cohort study. Lancet Diabetes Endocrinol 3 (2015), 605–614.
9. Scheen, AJ, Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease. Expert Opin Drug Metab Toxicol 9 (2013), 529–550.
10. Inzucchi, SE, Bergenstal, RM, Buse, JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 38 (2015), 140–149.
11. de Boer, IH, Bakris, G, Cannon, CP, Individualizing blood pressure targets for people with diabetes and hypertension: comparing the ADA and the ACC/AHA recommendations. JAMA 319 (2018), 1319–1320.
12. Strippoli, GF, Bonifati, C, Craig, M, Navaneethan, SD, Craig, JC, Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev, 4, 2006 CD006257.
13. Lewis, EJ, Hunsicker, LG, Clarke, WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 (2001), 851–860.
14. Brenner, BM, Cooper, ME, de Zeeuw, D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 (2001), 861–869.
15. Brenner, BM, Lawler, EV, Mackenzie, HS, The hyperfiltration theory: a paradigm shift in nephrology. Kidney Int 49 (1996), 1774–1777.
16. Tonneijck, L, Muskiet, MH, Smits, MM, et al. Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment. J Am Soc Nephrol 28 (2017), 1023–1039.
17. de Zeeuw, D, Remuzzi, G, Parving, HH, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 65 (2004), 2309–2320.
18. Fried, LF, Emanuele, N, Zhang, JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 369 (2013), 1892–1903.
19. Parving, HH, Brenner, BM, McMurray, JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 367 (2012), 2204–2213.
20. Packham, DK, Wolfe, R, Reutens, AT, et al. Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy. J Am Soc Nephrol 23 (2012), 123–130.
21. Mann, JF, Green, D, Jamerson, K, et al. Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 21 (2010), 527–535.
22. de Zeeuw, D, Akizawa, T, Audhya, P, et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med 369 (2013), 2492–2503.
23. Heerspink, HJ, Perkins, BA, Fitchett, DH, Husain, M, Cherney, DZ, Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 134 (2016), 752–772.
24. Wright, EM, Loo, DD, Hirayama, BA, Biology of human sodium glucose transporters. Physiol Rev 91 (2011), 733–794.
25. +-glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: involvement of hepatocyte nuclear factor-1α expression and activity. Endocrinology 149 (2008), 717–724.
26. Rahmoune, H, Thompson, PW, Ward, JM, Smith, CD, Hong, G, Brown, J, Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 54 (2005), 3427–3434.
27. van Bommel, EJ, Muskiet, MH, Tonneijck, L, Kramer, MH, Nieuwdorp, M, van Raalte, DH, SGLT2 inhibition in the diabetic kidney—from mechanisms to clinical outcome. Clin J Am Soc Nephrol 12 (2017), 700–710.
28. Zaccardi, F, Webb, DR, Htike, ZZ, Youssef, D, Khunti, K, Davies, MJ, Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obes Metab 18 (2016), 783–794.
29. Heerspink, HJL, Kosiborod, M, Inzucchi, SE, Cherney, DZI, Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney Int 94 (2018), 26–39.
30. Devenny, JJ, Godonis, HE, Harvey, SJ, Rooney, S, Cullen, MJ, Pelleymounter, MA, Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats. Obesity (Silver Spring) 20 (2012), 1645–1652.
31. Horie, I, Abiru, N, Hongo, R, et al. Increased sugar intake as a form of compensatory hyperphagia in patients with type 2 diabetes under dapagliflozin treatment. Diabetes Res Clin Pract 135 (2018), 178–184.
32. Komoroski, B, Vachharajani, N, Boulton, D, et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther 85 (2009), 520–526.
33. Weber, MA, Mansfield, TA, Cain, VA, Iqbal, N, Parikh, S, Ptaszynska, A, Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Diabetes Endocrinol 4 (2016), 211–220.
34. Muskiet, MHA, van Bommel, EJ, van Raalte, DH, Antihypertensive effects of SGLT2 inhibitors in type 2 diabetes. Lancet Diabetes Endocrinol 4 (2016), 188–189.
35. Zinman, B, Wanner, C, Lachin, JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
36. Neal, B, Perkovic, V, Mahaffey, KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377 (2017), 644–657.
37. Perkovic, V, Zeeuw, D, Mahaffey, KW, et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol 6 (2018), 691–704.
38. Wiviott, DS, Raz, I, Bonaca, MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med, 2018 published online DOI:1056/NEJMoa1812389.
39. Wanner, C, Inzucchi, SE, Lachin, JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375 (2016), 323–334.
40. Cherney, DZI, Zinman, B, Inzucchi, SE, et al. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 5 (2017), 610–621.
41. Neuen, BL, Ohkuma, T, Neal, B, et al. Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function: data from the CANVAS Program. Circulation, 2018 published online June 25. DOI:10.1161/CIRCULATIONAHA.118.035901.
42. Muskiet, MHA, van Baar, MJB, Scholtes, RA, van Raalte, DH, Renal outcomes in CVOTs: keep calm and carry on. Lancet Diabetes Endocrinol 6 (2018), 674–676.
43. + exchanger isoform 3 activity in the renal proximal tubule. J Am Soc Nephrol 25 (2014), 2028–2039.
44. Cherney, DZ, Perkins, BA, Soleymanlou, N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129 (2014), 587–597.
45. Wanner, C, Heerspink, HJL, Zinman, B, et al. Empagliflozin and kidney function decline in patients with type 2 diabetes: A slope analysis from the EMPA REG OUTCOME trial. J Am soc Nephrol 29 (2018), 2755–2769.
46. Holtkamp, FA, de Zeeuw, D, Thomas, MC, et al. An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int 80 (2011), 282–287.
47. Mudaliar, S, Alloju, S, Henry, RR, Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis. Diabetes Care 39 (2016), 1115–1122.
48. Muskiet, MHA, Tonneijck, L, Smits, MM, et al. GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. Nat Rev Nephrol 13 (2017), 605–628.
49. Tahrani, AA, Barnett, AH, Bailey, CJ, Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus. Nat Rev Endocrinol 12 (2016), 566–592.
50. Deacon, CF, Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab 13 (2011), 7–18.
51. Summary of product characteristics—dapagliflozin. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002322/WC500136026.pdf. (Accessed 21 August 2018)
52. Summary of product characteristics—empagliflozin. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002677/WC500168592.pdf. (Accessed 21 August 2018)
53. Summary of product characteristics—canagliflozin. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002649/WC500156456.pdf. (Accessed 21 August 2018)
54. Petrykiv, S, Sjostrom, CD, Greasley, PJ, Xu, J, Persson, F, Heerspink, HJL, Differential effects of dapagliflozin on cardiovascular risk factors at varying degrees of renal function. Clin J Am Soc Nephrol 12 (2017), 751–759.
55. 1c reductions with empagliflozin. Kidney Int 93 (2018), 231–244.
56. Wanner, C, Lachin, JM, Inzucchi, SE, et al. Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. Circulation 137 (2018), 119–129.
57. Heerspink, HJ, Desai, M, Jardine, M, Balis, D, Meininger, G, Perkovic, V, Canagliflozin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrol 28 (2017), 368–375.
58. Jardine, MJ, Mahaffey, KW, Neal, B, et al. The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) study rationale, design, and baseline characteristics. Am J Nephrol 46 (2017), 462–472.
59. Dekkers, CCJ, Gansevoort, RT, Heerspink, HJL, New diabetes therapies and diabetic kidney disease progression: the role of SGLT-2 inhibitors. Curr Diab Rep, 18, 2018, 27.
60. Boehringer Ingelheim and Lilly announce an academic collaboration with University of Oxford to investigate the effects of empagliflozin in people with chronic kidney disease. https://www.boehringer-ingelheim.com/EMPA-KIDNEY. (Accessed 21 August 2018)
61. Drucker, DJ, Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab 27 (2018), 740–756.
62. Smits, MM, Tonneijck, L, Muskiet, MH, Kramer, MH, Cahen, DL, van Raalte, DH, Gastrointestinal actions of glucagon-like peptide-1-based therapies: glycaemic control beyond the pancreas. Diabetes Obes Metab 18 (2016), 224–235.
63. Nauck, MA, Meier, JJ, The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. Lancet Diabetes Endocrinol 4 (2016), 525–536.
64. Defronzo, RA, From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58 (2009), 773–795.
65. Nauck, MA, Sauerwald, A, Ritzel, R, Holst, JJ, Schmiegel, W, Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure. Diabetes Care 21 (1998), 1925–1931.
66. Sun, F, Chai, S, Li, L, et al. Effects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysis. J Diabetes Res, 2015, 2015, 157201.
67. Aaboe, K, Knop, FK, Vilsboll, T, et al. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevent s degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus. Diabetes Obes Metab 12 (2010), 323–333.
68. Sun, F, Wu, S, Guo, S, et al. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Res Clin Pract 110 (2015), 26–37.
69. Muskiet, MH, Smits, MM, Morsink, LM, Diamant, M, The gut-renal axis: do incretin-based agents confer renoprotection in diabetes?. Nat Rev Nephrol 10 (2014), 88–103.
70. Skov, J, Dejgaard, A, Frokiaer, J, et al. Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men. J Clin Endocrinol Metab 98 (2013), E664–E671.
71. Muskiet, MH, Tonneijck, L, Smits, MM, et al. Acute renal haemodynamic effects of glucagon-like peptide-1 receptor agonist exenatide in healthy overweight men. Diabetes Obes Metab 18 (2016), 178–185.
72. Skov, J, Pedersen, M, Holst, JJ, et al. Short-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial. Diabetes Obes Metab 18 (2016), 581–589.
73. Tonneijck, L, Muskiet, MHA, Smits, MM, et al. Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: an 8-week, randomised, open-label trial. Diabetes Obes Metab 19 (2017), 1669–1680.
74. Tonneijck, L, Smits, MM, Muskiet, MHA, et al. Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial. Diabetologia 59 (2016), 1412–1421.
75. Tonneijck, L, Smits, MM, Muskiet, MH, et al. Renal effects of DPP-4 inhibitor sitagliptin or GLP-1 receptor agonist liraglutide in overweight patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 39 (2016), 2042–2050.
76. 1–67 in patients with type 2 diabetes. Diabetes Care 40 (2017), 1073–1081.
77. Davies, MJ, Bergenstal, R, Bode, B, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA 314 (2015), 687–699.
78. Davies, MJ, Bain, SC, Atkin, SL, et al. Efficacy and safety of liraglutide versus placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA-RENAL): a randomized clinical trial. Diabetes Care 39 (2016), 222–230.
79. von Scholten, BJ, Persson, F, Rosenlund, S, et al. The effect of liraglutide on renal function: a randomized clinical trial. Diabetes Obes Metab 19 (2017), 239–247.
80. Tuttle, KR, McKinney, TD, Davidson, JA, Anglin, G, Harper, KD, Botros, FT, Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials. Diabetes Obes Metab 19 (2017), 436–441.
81. Tuttle, KR, Lakshmanan, MC, Rayner, B, et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol 6 (2018), 605–617.
82. Pfeffer, MA, Claggett, B, Diaz, R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 373 (2015), 2247–2257.
83. Muskiet, MHA, Tonneijck, L, Huang, Y, et al. Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 6 (2018), 859–869.
84. Mann, JFE, Orsted, DD, Brown-Frandsen, K, et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 377 (2017), 839–848.
85. Hernandez, AF, Green, JB, Janmohamed, S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 392 (2018), 1519–1529.
86. Marso, SP, Bain, SC, Consoli, A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375 (2016), 1834–1844.
87. Mann, JFE, Orsted, DD, Buse, JB, Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 377 (2017), 2197–2198.
88. Cooper, ME, Perkovic, V, McGill, JB, et al. Kidney disease end points in a pooled analysis of individual patient-level data from a large clinical trials program of the dipeptidyl peptidase 4 inhibitor linagliptin in type 2 diabetes. Am J Kidney Dis 66 (2015), 441–449.
89. Groop, PH, Cooper, ME, Perkovic, V, Emser, A, Woerle, HJ, von Eynatten, M, Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diabetes Care 36 (2013), 3460–3468.
90. Groop, PH, Cooper, ME, Perkovic, V, et al. Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial. Diabetes Obes Metab 19 (2017), 1610–1619.
91. Mosenzon, O, Leibowitz, G, Bhatt, DL, et al. Effect of saxagliptin on renal outcomes in the SAVOR-TIMI 53 trial. Diabetes Care 40 (2017), 69–76.
92. Green, JB, Bethel, MA, Armstrong, PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373 (2015), 232–242.
93. Gantz, I, Chen, M, Suryawanshi, S, et al. A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus. Cardiovasc Diabetol, 16, 2017, 112.
94. Rosenstock, J, Perkovic, V, Johansen, OE, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA, 2018 published online Nov 9. DOI:10.1001/jama.2018.18269.
95. Barton, M, Yanagisawa, M, Endothelin: 20 years from discovery to therapy. Can J Physiol Pharmacol 86 (2008), 485–498.
96. Kohan, DE, Rossi, NF, Inscho, EW, Pollock, DM, Regulation of blood pressure and salt homeostasis by endothelin. Physiol Rev 91 (2011), 1–77.
97. Stuart, D, Chapman, M, Rees, S, Woodward, S, Kohan, DE, Myocardial, smooth muscle, nephron, and collecting duct gene targeting reveals the organ sites of endothelin A receptor antagonist fluid retention. J Pharmacol Exp Ther 346 (2013), 182–189.
98. Stuart, D, Rees, S, Woodward, SK, Koesters, R, Strait, KA, Kohan, DE, Disruption of the endothelin A receptor in the nephron causes mild fluid volume expansion. BMC Nephrol, 13, 2012, 166.
99. Kohan, DE, Barton, M, Endothelin and endothelin antagonists in chronic kidney disease. Kidney Int 86 (2014), 896–904.
100. Saleh, MA, Pollock, JS, Pollock, DM, Distinct actions of endothelin A-selective versus combined endothelin A/B receptor antagonists in early diabetic kidney disease. J Pharmacol Exp Ther 338 (2011), 263–270.
101. Dhaun, N, Ferro, CJ, Davenport, AP, Haynes, WG, Goddard, J, Webb, DJ, Haemodynamic and renal effects of endothelin receptor antagonism in patients with chronic kidney disease. Nephrol Dial Transplant 22 (2007), 3228–3234.
102. Dhaun, N, Macintyre, IM, Melville, V, et al. Blood pressure-independent reduction in proteinuria and arterial stiffness after acute endothelin-a receptor antagonism in chronic kidney disease. Hypertension 54 (2009), 113–119.
103. Boels, MG, Avramut, MC, Koudijs, A, et al. Atrasentan reduces albuminuria by restoring the glomerular endothelial glycocalyx barrier in diabetic nephropathy. Diabetes 65 (2016), 2429–2439.
104. Barton, M, Tharaux, PL, Endothelin and the podocyte. Clin Kidney J 5 (2012), 17–27.
105. Barton, M, Shaw, S, d'Uscio, LV, Moreau, P, Luscher, TF, Angiotensin II increases vascular and renal endothelin-1 and functional endothelin converting enzyme activity in vivo: role of ETA receptors for endothelin regulation. Biochem Biophys Res Commun 238 (1997), 861–865.
106. Wenzel, RR, Littke, T, Kuranoff, S, et al. Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J Am Soc Nephrol 20 (2009), 655–664.
107. de Zeeuw, D, Coll, B, Andress, D, et al. The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. J Am Soc Nephrol 25 (2014), 1083–1093.
108. Heerspink, HJL, Andress, DL, Bakris, G, et al. Rationale and protocol of the study of diabetic nephropathy with atrasentan (SONAR) trial: a clinical trial design novel to diabetic nephropathy. Diabetes Obes Metab 20 (2018), 1369–1376.
109. Epstein, M, Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications. Am J Kidney Dis 37 (2001), 677–688.
110. Messaoudi, S, Azibani, F, Delcayre, C, Jaisser, F, Aldosterone, mineralocorticoid receptor, and heart failure. Mol Cell Endocrinol 350 (2012), 266–272.
111. Bolignano, D, Palmer, SC, Navaneethan, SD, Strippoli, GF, Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev, 4, 2014 CD007004.
112. Chrysostomou, A, Becker, G, Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med 345 (2001), 925–926.
113. Epstein, M, Williams, GH, Weinberger, M, et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 1 (2006), 940–951.
114. Morales, E, Millet, VG, Rojas-Rivera, J, et al. Renoprotective effects of mineralocorticoid receptor blockers in patients with proteinuric kidney diseases. Nephrol Dial Transplant 28 (2013), 405–412.
115. Lazich, I, Bakris, GL, Prediction and management of hyperkalemia across the spectrum of chronic kidney disease. Semin Nephrol 34 (2014), 333–339.
116. Bomback, AS, Kshirsagar, AV, Amamoo, MA, Klemmer, PJ, Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Am J Kidney Dis 51 (2008), 199–211.
117. Roscioni, SS, de Zeeuw, D, Bakker, SJ, Lambers Heerspink, HJ, Management of hyperkalaemia consequent to mineralocorticoid-receptor antagonist therapy. Nat Rev Nephrol 8 (2012), 691–699.
118. Kolkhof, P, Borden, SA, Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics. Mol Cell Endocrinol 350 (2012), 310–317.
119. Barfacker, L, Kuhl, A, Hillisch, A, et al. Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem 7 (2012), 1385–1403.
120. Bakris, GL, Agarwal, R, Chan, JC, et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA 314 (2015), 884–894.
121. Tuomi, T, Santoro, N, Caprio, S, Cai, M, Weng, J, Groop, L, The many faces of diabetes: a disease with increasing heterogeneity. Lancet 383 (2014), 1084–1094.
122. de Zeeuw, D, Heerspink, HJL, Jardine, M, Perkovic, V, Renal trials in diabetes need a platform: time for a global approach?. Lancet Diabetes Endocrinol 6 (2018), 356–358.
123. van Baar, MJB, van Ruiten, CC, Muskiet, MHA, van Bloemendaal, L, IJzerman van, RG, Raalte, DH, SGLT2 inhibitors in combination therapy: from mechanisms to clinical considerations in type 2 diabetes management. Diabetes Care 41 (2018), 1543–1556.
124. Frias, JP, Guja, C, Hardy, E, et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol 4 (2016), 1004–1016.
125. Ludvik, B, Frias, JP, Tinahones, FJ, et al. Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 6 (2018), 370–381.